A5019253682- Childhood Cancer Survivors' Quality of Life
- Acute Lymphoblastic Leukemia research
- Adolescent and Pediatric Healthcare
- Ethics and Legal Issues in Pediatric Healthcare
- Palliative Care and End-of-Life Issues
- Family Support in Illness
- Global Cancer Incidence and Screening
- Chromatin Remodeling and Cancer
- Neuroendocrine Tumor Research Advances
- Patient Dignity and Privacy
- Cancer Risks and Factors
- Neuroblastoma Research and Treatments
University of South Carolina
2024
University of Alabama at Birmingham
2017-2022
Children's of Alabama
2020
Obesity at diagnosis of childhood acute lymphoblastic leukemia (ALL) is associated with greater risk relapse; whether this association extends to obesity during maintenance unstudied.
Background Poor mercaptopurine (6MP) adherence (mean rate < 90%) increases the relapse risk among children with acute lymphoblastic leukemia (ALL). 6MP remains difficult to measure in real time. Easily measured patient‐level factors could identify patients at for poor adherence. Methods The authors via electronic monitoring 6 months per patient. Using data from month 3, they created a prediction model nonadherence 407 ALL age, 7.7 ± 4.4 years); used receiver operating characteristic...
Childhood cancer survivors carry a high burden of late-occurring treatment-related morbidity. Long-term risk-based anticipatory surveillance allows for early detection and management complications. We sought to examine demographic, clinical, social characteristics associated with survivorship clinic attendance at the Taking on Life after Cancer (TLC) Clinic Children's Hospital Alabama.
Abstract Background: One-fifth of U.S. counties are designated persistent child poverty (≥20% children in since 1980). The association between a environment and mortality with cancer is unknown. Methods: Our cohort includes 2,089 (2000–2016) Alabama. We used multivariable Cox proportional hazards modeling (adjusted for sociodemographics/clinical characteristics) to assess by designation at 1, 5, 10 years from diagnosis. Distance treatment was subsequently explored. Results: Forty-two percent...
10530 Background: Poor adherence to 6MP (measured electronically [MEMS]) increases relapse risk in children with ALL (Bhatia et al. JAMA Oncol 2015). Adherence is difficult assess clinically and non-adherers are more likely over-report intake (Landier Blood 2017). Key sociodemographic/clinical factors JCO 2012) red cell methyl-mercaptopurine (MMP, a metabolite) levels (Hoppmann ASCO 2017) associated non-adherence could potentially identify non-adherers. Methods: We developed prediction model...
To the Editor: As a first-year pediatric oncology fellow, I had patient with an aggressive, metastatic tumor. Like other trainees and clinicians, received benefited from training in delivering bad news.1 Still, felt unprepared to navigate my first conversation about end of life patient’s mother. Though prognosis was poor, he remarkable initial response chemotherapy. He discharged home celebrated Christmas among family. His grandfather shook hand as they left hospital, saying, “This is best...
10514 Background: Non-adherence to 6MP (monitored with medication event monitoring system [MEMs]) is associated an increased risk of relapse in children ALL.(JAMA Oncol, 2015) Self-report over-estimates true intake, particularly non-adherent patients.(Blood, 2017) However, adherence using MEMs logistically difficult. We investigated whether red cell metabolite levels (thioguanine nucleotide [TGN] and methylated mercaptopurine [MMP]) taken together, could identify patients. Methods: The...